OCT 16 - 17 2013
Cancer: Research, Discovery and Therapeutics 2013
1233 29 46596

BioConference Live makes it easier and more cost-effective for the cancer research community to come together online through live video webcasts and real-time networking. BioConference Live attendees learn new concepts, tools and techniques that they can apply to research and diagnosis. BioConference Live requires no travel or time away from the lab or hospital, yet delivers all the benefits of a physical conference. Attendees can earn free CME and CE Credits.

Topics will include Epigenetics, Drug Discovery, Therapeutics, Detection, Stem Cells, Cancer Evolution and Resistance, Bone Marrow, Global Cancer Crisis, Brain Cancer, Cancer Genetics, Nanotechnology, Lung Cancer, Obesity, Energy Balance, and Metabolism, Colon Cancer, Cell Technologies, Breast Cancer, Prostate Cancer, Vaccines, Pancreatic Cancer, Melanoma, Liver Cancer, Lymphoma, Leukemia, Biomarkers, Monoclonal Antibodies, Cervical Cancer, Chromatin, Epigenetics, Immunology, Drug Development, Molecular Diagnostics, Signaling, Research Funding, Kinome/Kinase, Cell Engineering, Next-Generation Sequencing, and other topics.

This event will bring together research scientists, post docs, principal investigators, lab directors and professionals from around the world to learn about recent advances in cancer research. This conference offers an amazing opportunity as it is free to participants, and there will be no out-of-pocket expenses for travel. However, participants will still benefit from interacting with a global community of like-minded colleagues, without leaving the comfort of their office or home.

Conference participants will be able to
 

  • Attend interactive live streaming video sessions
  • Have their questions answered in real-time by industry experts
  • Chat live with peers and speakers
  • Browse a virtual exhibit floor for solution providers
  • Earn free CME and CE continuing education credits


No crowded airports, delayed flights or expensive hotel rooms, but still the look and feel of a first-rate conference with world renowned experts. Participants also benefit from the fact that experts and vendors are more accessible, no more waiting in line to speak to someone. Think it is too good to be true? Checkout the venue and become a believer.

 


Speakers:
  • Director, Research Department, Centro di Ricerche Oncologiche di Mercogliano, Naples, Italy
  • Chair of the Division of Clinical Core Laboratory Services in the Department of Laboratory Medicine , Mayo Clinic College of Medicine
  • Chief Scientific Officer, Sequenom
  • Scientific Researcher, Dana-Farber Cancer Institute
  • Associate Professor of Pathology, Clinical Toxicology, Director, Point-of-Care Testing, Johns Hopkins University School of Medicine
  • Founder, President, CEO, TED Fellow, Rare Genomics Institute Washington University in St. Louis
  • Senior Manager, NGS Applications, DNASTAR
  • Clinical Chemistry Fellow, Dept of Pathology, University of Louisville
  • Professor, Director & Vice Chair of Urologic Research, Carl Rosen Professorship in Urology, Departments of Urology, Mayo Clinic College of Medicine
  • Chief Scientist, Complex Adaptive Systems, Regents' Professor and Del E. Webb Chair in Health I, Arizona State University
  • Assistant Professor, Department of Surgery,, Massachusetts General Hospital and Harvard Medical School
  • Chief Scientific Officer, Bioscale
  • Director of Computational Sciences and Informatics program for Complex Adaptive Systems at Arizona S, Professor in the School of Life Sciences in ASU's College of Liberal Arts and Sciences, A
  • Assistant Professor Department of Surgery, Division of General Surgery, Indiana University School of Medicine Indiana University Melvin and Bren Simon Cancer Center IU Center for Computationa
  • Associate Professor, Department of Biology & the Cancer Research Program , North Carolina Central University, Durham, North Carolina; Adjunct Professor, School of Medicine, Department of
  • Associate Director, Product Applications, Genetic Analysis Division, Life Technologies
  • Head of Medical Science Informatics, Life Technologies
  • Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco School of Medicine
  • Associate Professor, Department of Biological Sciences, Development and Disease, Purdue University
  • Associate Professor of Medicine and Surgery, Duke Cancer Institute, Divisions of Medical Oncology and Urology, Duke University
  • Associate Professor and Assistant Head, Department of Biological Sciences, Purdue University
  • Assistant Professor, Assistant Investigator, Abramson Family Cancer Research Institute, University of Pennsylvania Medicine
  • Distinguished Professor of Genetics, Scientific Director of Genomics and Bioinformatics, University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center
  • Co-Director, Complex Adaptive Systems Initiative, Director, Transformative Healthcare Networks, Professor, School of Life Sciences, Arizona State University (ASU)
  • Associate Dean of the Graduate School of Biological Sciences and Professor of Oncological Sciences, Icahn School of Medicine at Mount Sinai
  • Professor, Public Health Research Institute, New Jersey Medical School, Rutgers University
  • Associate Professor of Surgery, Division of Adult Cardiothoracic Surgery, Chief of General Thoracic Surgery, University of California, San Francisco, VA Medical Center
  • Principal Investigator, Structure and Function of the Cell Nucleus research unit, Full Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Instit
  • Associate Professor of Cancer Biology, University College Dublin School of Biomolecular & Biomedical Science
  • Assistant Professor, Biomedical Diagnostic & Therapeutic Sciences, , Oakland University
  • Associate Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center
  • Assistant Professor, Department of Systems & Computational Biology, Assistant Professor, Department of Epidemiology & Population Health, Albert Einstein College of Medicine
  • Associate Professor in Pathology, Harvard Medical School, Department of Pathology, Children's Hospital Boston
  • James H Semans MD Professor of Surgery, Division of Urologic Surgery, , Director, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center
  • Associate Professor of Pediatrics, Director, Pediatric Familial Cancer Clinic, University of Chicago
  • Senior Investigator, National Cancer Institute, Center for Cancer Research
  • Scientific Projects Manager, TARGET, NCI Office of Cancer Genomics

Show Resources
Agenda
  • OCT 16, 2013 06:00 AM PDT
    Speaker: Nicola Normanno, MD
  • OCT 16, 2013 07:00 AM PDT
    Speaker: Kathryn E Wellen, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 07:00 AM PDT
    Speaker: R Claudio Aguilar, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 07:00 AM PDT
    Speaker: Andrew Armstrong, MD ScM FACP
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 09:00 AM PDT
    Speaker: Charles M. Perou, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 10:00 AM PDT
    Speaker: Anna Barker, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 11:00 AM PDT
    Speaker: Ross L. Cagan, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 11:00 AM PDT
    Speaker: Michael J Mann, MD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 11:00 AM PDT
    Speaker: Fred Kramer, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 12:00 PM PDT
    Speaker: William M. Gallagher, PhD.
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 12:00 PM PDT
    Speaker: Katherine LB Borden, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 01:00 PM PDT
    Speaker: Jessica C Mar, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 01:00 PM PDT
    Speaker: Kristin Landis-Piwowar, PhD, MLS
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 01:00 PM PDT
    Speaker: Elahe A Mostaghel, MD, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 02:00 PM PDT
    Speaker: Roberto Chiarle, MD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 02:00 PM PDT
    Speaker: Judd W Moul, MD, FACS
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 03:00 PM PDT
    Speaker: Adil Daud, MD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 03:00 PM PDT
    Speaker: Henry Chang, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 06:00 AM PDT
    Speaker: Dan Rhodes, PhD
  • OCT 17, 2013 07:00 AM PDT
    Speaker: Michaela Bowden, PhD
  • OCT 17, 2013 07:00 AM PDT
    Speaker: Allan S. Jaffe, MD.
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 07:00 AM PDT
    Speaker: Charles Cantor, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 08:00 AM PDT
    Speaker: C Jimmy Lin, MD, PhD, MHS
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 08:00 AM PDT
    Speaker: William Clarke, PhD, MBA, DABCC
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 09:00 AM PDT
    Speaker: Lori M. Millner, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 09:00 AM PDT
    Speaker: Matthew Keyser, MS
  • OCT 17, 2013 10:00 AM PDT
    Speaker: Donald Tindall, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 11:00 AM PDT
    Speaker: George Poste, DVM, DSc, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 12:00 PM PDT
    Speaker: Martin Latterich, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 12:00 PM PDT
    Speaker: Daniel Irimia, MD, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 12:00 PM PDT
    Speaker: Kenneth Buetow, PhD, FACMI
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 01:00 PM PDT
    Speaker: Milan Radovich, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 02:00 PM PDT
    Speaker: Stephen Jackson, PhD
  • OCT 17, 2013 02:00 PM PDT
    Speaker: Antonio T. Baines, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 03:00 PM PDT
    Speaker: Kenan Onel MD, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 23, 2013 12:00 PM PDT
    Speaker: Len Neckers
  • NOV 08, 2013 12:00 PM PST
    Speaker: Jaime Guidry Auvil, PhD
  • OCT 16, 2013 06:00 AM PDT
    Speaker: Nicola Normanno, MD
  • OCT 16, 2013 07:00 AM PDT
    Speaker: Kathryn E Wellen, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 07:00 AM PDT
    Speaker: R Claudio Aguilar, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 07:00 AM PDT
    Speaker: Andrew Armstrong, MD ScM FACP
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 09:00 AM PDT
    Speaker: Charles M. Perou, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 10:00 AM PDT
    Speaker: Anna Barker, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 11:00 AM PDT
    Speaker: Ross L. Cagan, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 11:00 AM PDT
    Speaker: Michael J Mann, MD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 11:00 AM PDT
    Speaker: Fred Kramer, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 12:00 PM PDT
    Speaker: William M. Gallagher, PhD.
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 12:00 PM PDT
    Speaker: Katherine LB Borden, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 01:00 PM PDT
    Speaker: Jessica C Mar, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 01:00 PM PDT
    Speaker: Kristin Landis-Piwowar, PhD, MLS
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 01:00 PM PDT
    Speaker: Elahe A Mostaghel, MD, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 02:00 PM PDT
    Speaker: Roberto Chiarle, MD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 02:00 PM PDT
    Speaker: Judd W Moul, MD, FACS
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 03:00 PM PDT
    Speaker: Adil Daud, MD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 16, 2013 03:00 PM PDT
    Speaker: Henry Chang, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 06:00 AM PDT
    Speaker: Dan Rhodes, PhD
  • OCT 17, 2013 07:00 AM PDT
    Speaker: Michaela Bowden, PhD
  • OCT 17, 2013 07:00 AM PDT
    Speaker: Allan S. Jaffe, MD.
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 07:00 AM PDT
    Speaker: Charles Cantor, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 08:00 AM PDT
    Speaker: C Jimmy Lin, MD, PhD, MHS
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 08:00 AM PDT
    Speaker: William Clarke, PhD, MBA, DABCC
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 09:00 AM PDT
    Speaker: Lori M. Millner, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 09:00 AM PDT
    Speaker: Matthew Keyser, MS
  • OCT 17, 2013 10:00 AM PDT
    Speaker: Donald Tindall, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 11:00 AM PDT
    Speaker: George Poste, DVM, DSc, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 12:00 PM PDT
    Speaker: Martin Latterich, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 12:00 PM PDT
    Speaker: Daniel Irimia, MD, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 12:00 PM PDT
    Speaker: Kenneth Buetow, PhD, FACMI
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 01:00 PM PDT
    Speaker: Milan Radovich, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 02:00 PM PDT
    Speaker: Stephen Jackson, PhD
  • OCT 17, 2013 02:00 PM PDT
    Speaker: Antonio T. Baines, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 17, 2013 03:00 PM PDT
    Speaker: Kenan Onel MD, PhD
    SEE ABSTRACT | Continuing Education: CE
  • OCT 23, 2013 12:00 PM PDT
    Speaker: Len Neckers
  • NOV 08, 2013 12:00 PM PST
    Speaker: Jaime Guidry Auvil, PhD
Speakers

  • Nicola Normanno, MD
    Director, Research Department, Centro di Ricerche Oncologiche di Mercogliano, Naples, Italy
    Biography
      Dr. Normanno earned his Medical Doctor Degree in 1988 at the Medical School of the University of Naples (Italy) Federico II. He received his spacialization in Medical Oncology in 1991, and in Hematology in 2001, at the same university. Between 1990 and 1993, Dr. Normanno completed a postoctoral fellowship studying tumor growth factors at the National Institutes of Health, Bethesda, MD. Since 1993, Dr. Normanno's areas of research have been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the use of antisense oligonucleotides and inhibitors of receptors in experimental models of molecular therapy of carcinomas; and identification of markers of response or resistance to anti EGFR agents. Dr. Normanno is a member of the American Association for Cancer Research, the Italian Tumor Society, and the Italian Cancer Society. He is the author of over 140 papers published in peer reviewed journals. After serving as Senior Investigator, and later, Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Chief of the Cell Biology and Biotherapy Unit at the same Hospital, and since 2006, is also Director of the Research Department.
    • Allan S. Jaffe, MD.
      Chair of the Division of Clinical Core Laboratory Services in the Department of Laboratory Medicine , Mayo Clinic College of Medicine
      Biography
        The focus of Dr. Jaffes research has been the development and implementation clinically of biomarkers of cardiac injury, hemodynamic stress and coagulation in the acute cardiac care setting. Of late his focus has been mostly on markers of cardiac injury and particularly cardiac troponin and to some extent on hemodynamic stress and particularly natriuretic peptides. He has participated in or directed many of the major national and international guidelines initiatives in these areas which include efforts to define the criteria for the diagnosis of acute myocardial infarction. His research activities include a broad range of involvement from basic investigation, assay development, clinical translation and clinical implementation. Publications at each level, usually with collaborators have been developed. At present he has NIH funding as part of a project to define the changing incidence of AMI in the community and to study the use of novel natriuretic peptides in the setting of acute ischemic heart disease. In addition, Dr. Jaffe directs ongoing efforts collecting blood samples on patients who present to the Emergency Department with symptoms compatible with ischemia.
      • Charles Cantor, PhD
        Chief Scientific Officer, Sequenom
        Biography
          Dr. Charles Cantor is a founder, and Chief Scientific Officer at SEQUENOM, Inc., which is a genetics discovery company with tools, information and strategies for determining the medical impact of genes and genetic variations. He is also the founder of SelectX Pharmaceuticals, a drug discovery company, Retrotope, an anti-aging company, and DiThera, a biotherapeutic company. Dr. Cantor is professor emeritus of Biomedical Engineering and of Pharmacology and was the director of the Center for Advanced Biotechnology at Boston University. He is currently adjunct professor of Bioengineering at UC San Diego, adjunct professor of Molecular Biology at the Scripps Institute for Research, and distinguished adjunct professor of Physiology and Biophysics at UC Irvine. Prior to this, Dr. Cantor held positions in Chemistry and then in Genetics and Development at Columbia University and in Molecular Biology at the University of California at Berkeley. Cantor was educated in chemistry at Columbia College (AB) and at the University of California Berkeley (PhD). Dr. Cantor has been granted more than 60 US patents and, with Paul Schimmel, wrote a three-volume textbook on biophysical chemistry. He also co-authored the first textbook on Genomics titled 'The Science and Technology of the Human Genome Project'. In addition, he sits on the advisory boards of numerous national and international biotechnology firms, has published more than 450 peer-reviewed articles, and is a member of the U.S. National Academy of Sciences.
        • Michaela Bowden, PhD
          Scientific Researcher, Dana-Farber Cancer Institute
          Biography
            Michaela Bowden received her Ph.D. from Dublin City University in Ireland and went on to complete a Post-Doctoral Research Fellowship at Tufts University. She then spent 4years as a Research Fellow at Novartis Institutes for Biomedical Research, Inc, in Cambridge MA. Dr. Bowden has a strong interdisciplinary skill set with an emphasis on biomarker discovery utilizing cellular and molecular biology techniques. She has previously worked on identifying and evaluating candidate oncogenic biomarkers of small molecule inhibition with a view to elucidating the underlying mechanism of action through analysis of the associated signaling pathways. Dr. Bowden is very interested in molecular characterization of potential prognostic biomarkers of prostate cancer and in developing the molecular approach to utilizing archival FFPE prostate cancer tissues most efficiently.
          • William Clarke, PhD, MBA, DABCC
            Associate Professor of Pathology, Clinical Toxicology, Director, Point-of-Care Testing, Johns Hopkins University School of Medicine
            Biography
              Dr. William Clarke is an associate professor of pathology at the Johns Hopkins University School of Medicine. His research focuses on the development of analytical methods for drug analysis, clinical mass spectrometry, and devices for point-of-care testing. Dr. Clarke serves as the director of Clinical Toxicology as well as Critical and Point-of-Care Testing Program at The Johns Hopkins Hospital. His team's current projects include qualitative screening for antiretroviral drugs and substances of abuse in various HIV- prevention clinical trials, development and validation of mass spectrometry methods for clinical analysis, and development of clinical assays for use on microfluidic platforms. Dr. Clarke received his B.S. in Chemistry from the University of Nebraska at Kearney and his Ph.D. in Analytical Chemistry from the University of Nebraska-Lincoln, as well as an M.B.A. from the Carey School of Business at Johns Hopkins University. He completed a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine.
            • C Jimmy Lin, MD, PhD, MHS
              Founder, President, CEO, TED Fellow, Rare Genomics Institute Washington University in St. Louis
              Biography
                Jimmy Lin, MD, PhD, MHS, is a 2012 TED Fellow and Founder & President of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Partnering with 18 of the top medical institutions, such as Harvard, Yale, Johns Hopkins, and Stanford, RGI helps custom design personalized research projects for diseases so rare that no organization exists to help. Dr. Lin is also a medical school faculty member at the Washington University in St. Louis and led the computational analysis of the first ever exome sequenching studies for any human disease at Johns Hopkins. He has numerous publications in Science, Nature, Cell, Nature Genetics, and Nature Biotechnology, and has been featured in Forbes, Bloomberg, Wall Street Journal, Washington Post, and the Huffington Post.
              • Matthew Keyser, MS
                Senior Manager, NGS Applications, DNASTAR
                Biography
                  Matthew Keyser is Senior Manager, NGS Applications for DNASTAR, where he has helped scientists address their sequence assembly and analysis challenges for the past seven years. Matts sole focus at DNASTAR is supporting customers in next-gen sequencing applications using DNASTARs broad software toolset. Matt helps customers with their templated and de novo assembly projects, transcriptomes, exomes, metagenomic assemblies, RNA-Seq, ChIP-Seq and numerous other unique experiments. Matt has helped hundreds of scientists optimize their workflows using DNASTARs next-gen software solutions. He has also spoken at numerous conferences and workshops regarding the capabilities of DNASTARs next-gen software tools.
                • Lori M. Millner, PhD
                  Clinical Chemistry Fellow, Dept of Pathology, University of Louisville
                  Biography
                    able Dr. Millner received her PhD in the field of pharmacology and toxicology from the University of Louisville where she studied gene-environmental interactions associated with breast cancer. Following completion of her PhD, she completed a 2 year NIH T32 fellowship in the Department of Pathology where she continued her research on breast cancer with a focus on circulating tumor cells. Currently, Dr. Millner is focusing on translating her initial circulating tumor cell research into a clinically useful assay as a Clinical Chemistry Fellow at the University of Louisville Hospital. She plans to integrate her clinical training and research background to develop diagnostics useful for early stage cancers. Dr. Millner has given talks this year at the American Association of Clinical Chemists and the Association for Clinical Scientists and has received numerous awards this year including the Young Scientist Award in Innovation of Science (ACS), Young Investigator Award in Molecular Pathology (AACC), Best Poster Award in Clinical Diagnostics and Immunology (AACC), and a travel award (AACC).
                  • Donald Tindall, PhD
                    Professor, Director & Vice Chair of Urologic Research, Carl Rosen Professorship in Urology, Departments of Urology, Mayo Clinic College of Medicine
                    Biography
                      Dr. Tindall holds the position of Director, Vice Chair and Professor of Urologic Research in the Department of Urology at Mayo Clinic in Rochester, Minnesota. Dr. Tindalls research interest is in the area of prostate cancer. Dr. Tindall currently serves on the editorial boards of several scientific journals (Cancer Prevention Research, Prostate, Associate Editor-Cancer Research, Cancer Letters, Current Cancer Therapy Reviews. Previously, Dr. Tindall has served on the editorial boards of Journal of Andrology (Co-Editor-in-Chief), Endocrinology, The Yearbook of Cancer, and Steroids. In addition, Dr. Tindall has chaired a number of international conferences. Dr. Tindall has been President of the Society for Basic Urologic Research (1991), Co-Chair of the Prostate Cancer Review Group (sponsored by the National Cancer Institute in 1997), and Chair of the National Cancer Institute Scientific Review Group Subcommittee C-Basic/Preclinical (2003-2004). Dr. Tindall has published over 220 original scientific papers and has written over 40 reviews and book chapters. He has received several awards, including that from American Men and Women of Science (1978), Men of Achievement (1980), Who's Who in Technology Today (1980), Leading Consultants in Technology (1981) and a Research Career Development Award from National Institutes of Health (1998-1999). 2009-Meritorious Achievement Award of the Society for Basic Urologic Research
                    • George Poste, DVM, DSc, PhD
                      Chief Scientist, Complex Adaptive Systems, Regents' Professor and Del E. Webb Chair in Health I, Arizona State University
                      Biography
                        Dr. George Poste is Chief Scientist, Complex Adaptive Systems Initiative (CASI), Regents Professor and Del E. Webb Chair in Health Innovation at Arizona State University. He assumed this post in February 2009. This program links expertise across the university in research on synthetic biology, ubiquitous sensing and healthcare informatics for personalized medicine. He founded the Biodesign Institute at ASU and served as Director for 2003 to 2009. In creating this Institute, Dr. Poste designed and built 400,000 sq. ft. of new facilities, achieved cumulative research funding of $300 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering. He serves on the Board of Directors of Monsanto (since 2003), Exelixis (since 2004), Caris Life Science (since 2005), and the Scientific Advisory Board of Synthetic Genomics (since 2009). From 1992 to 1999 he was Chief Science and Technology Officer and President, R&D of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004 he was named as R&D Scientist of the Year by R&D Magazine, in 2006 he received the Einstein award from the Global Business Leadership Council and in2009 received the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry. He has published over 350 research papers and edited 14 books on pharmaceutical technologies and oncology. He has received honorary degrees in science, law and medicine for his research contributions and was honored in 1999 by HM Queen Elizabeth II as a Commander of the British Empire for his contributions to international healthcare and security. He is a Fellow of the Royal Society, the Royal College of Pathologists and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution, Stanford University and a member of the Council for Foreign Relations. He served as a member of the Defense Science Board from 2003 to 2009 and Health Board of the US Department of Defense (DoD) and is currently a member of the US Institute of Medicine Board on Global Health. He has served as a member of Advisory Committees for multiple U.S. Government Agencies in areas of defense, national security and healthcare. Abstract:
                      • Daniel Irimia, MD, PhD
                        Assistant Professor, Department of Surgery,, Massachusetts General Hospital and Harvard Medical School
                        Biography
                          Dr. Irimia is an Assistant Professor in the Department of Surgery at the Massachusetts General Hospital, Shriners Hospitals for Children in Boston, and Harvard Medical School. He is leading a research program that is focused on studying the roles of cellular migration in health and disease. Dr. Irimia is interested in probing the role of cancer cell migration during cancer invasion and tumor metastasis. He is also very interested in understanding how the ability of white blood cells to move and protect against microbes is being affected during the systemic inflammation responses after burn and trauma injuries. For this research, he is employing the most advanced microscale technologies which enable us to design new tools and measure cell migration with better precision than ever before.
                        • Martin Latterich, PhD
                          Chief Scientific Officer, Bioscale
                          Biography
                            Dr. Latterich has nearly 20 years of academic and commercial and leadership experience and features an accomplished research career focused on the proteomics-based discovery of novel biomarkers in oncology, respiratory disease and neurodegenerative disorders. Martin is currently CSO at BioScale, a Lexington, MA, based biotechnology corporation commercializing a novel acoustic biomarker quantification platform. Most recently Martin served as a Professor at the Proteogenomics Research Institute for Systems Medicine in San Diego, where his laboratory used proteomics and genomics to discover novel biomarkers of cancer and degenerative disease though a systems biology approach that includes proteomics. He is also the CSO, co-founder and a board member for the non-profit Nicholas Conor Institute for Pediatric Cancer Research. Martin's work at the institute included designing new technologies to enable the better treatment of children with cancer, using personalized medicine technology to match their unique genetic make-up and tumor physiology to available treatment options. He previously served on the faculty of the University of Montreal, McGill University and the Salk Institute. His grant-funded work has been recognized by the 2003 Tier I Canada Research Chair, the 1998 Pew Scholar Award and the 1997 Basil O'Connor Starter Scholar Award. Dr. Latterich also held senior management positions at several biotechnology companies, including Diversa and Illumina, where he headed the proteomics initiatives. He has made significant contributions to the field of cell biology, clinical biomarker discovery, proteomics and genomics. Among his recent discoveries are biomarkers for cancer, respiratory disease and neurodegenerative disorders. Dr Latterich has edited one book on RNAi, is author on over 34 publications in leading scientific journals and is listed on numerous patent applications. Martin is Editor-in-Chief of the scientific journal Proteome Science. He has served on several national and international study sections. He was a postdoctoral fellow in molecular and cell biology in the laboratory of Dr. Randy Schekman at the HHMI and University of California, Berkeley. Dr. Latterich earned his Ph.D. in cell biology and a B.Sc. in biochemistry and molecular biology from Durham University, U.K.
                          • Kenneth Buetow, PhD, FACMI
                            Director of Computational Sciences and Informatics program for Complex Adaptive Systems at Arizona S, Professor in the School of Life Sciences in ASU's College of Liberal Arts and Sciences, A
                            Biography
                              Dr. Ken Buetow is a human genetics and genomics researcher who leverages computational tools to understand complex traits such as cancer, liver disease, and obesity. Dr. Buetow currently serves as Director of Computational Sciences and Informatics program for Complex Adaptive Systems at Arizona State University (CAS@ASU) and is a professor in the School of Life Sciences in ASU's College of Liberal Arts and Sciences. CAS@ASU applies systems approaches that leverage ASU's interdisciplinary research strengths to address complex global challenges. The Computational Sciences and Informatics program is developing and applying information technology to collect, connect, and enhance trans-disciplinary knowledge both within ASU and across the broader knowledge-generating ecosystems. CAS@ASU is creating a Next Generation Cyber Capability to address the challenges and opportunities afforded by "Big Data" and the emergence of 4th Paradigm Data Science. This capability brings state-of-the-art computational approaches to CAS@ASU's transdisciplinary, use-inspired research efforts Dr. Buetow previously served as the Director of the Center for Biomedical Informatics and Information Technology within the National Institutes of Health's National Cancer Institute (NCI). In that capacity he initiated and oversaw the NCI's efforts to connect the global cancer community through community-developed, standards-based, interoperable informatics capabilities that enable secure exchange and use of biomedical data. Buetow designed and built one of the largest biomedical computing efforts in the world. He was responsible for coordinating biomedical informatics and information technology at the NCI. The NCI center he led focused on speeding scientific discovery and facilitated translational research by coordinating, developing and deploying biomedical informatics systems, infrastructure, tools and data in support of NCI research initiatives.
                            • Milan Radovich, PhD
                              Assistant Professor Department of Surgery, Division of General Surgery, Indiana University School of Medicine Indiana University Melvin and Bren Simon Cancer Center IU Center for Computationa
                            • Antonio T. Baines, PhD
                              Associate Professor, Department of Biology & the Cancer Research Program , North Carolina Central University, Durham, North Carolina; Adjunct Professor, School of Medicine, Department of
                              Biography
                                Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a bachelors degree in biology from Norfolk State University and a doctorate in pharmacology and toxicology from the University of Arizona. Afterwards, Dr. Baines accepted a postdoctoral fellowship at UNC in pharmacology and radiation oncology under Drs. Channing Der and Adrienne Cox. His research focused on understanding the role of the Ras oncogene as a molecular target in pancreatic cancer oncogenesis. In August 2006, Dr. Baines accepted a tenure-track faculty position at NCCU where he currently teaches and conducts research as a cancer biologist. Also, he mentors high school, undergraduate, and graduate students in his laboratory. Pancreatic cancer is the 4th most common cause of cancer deaths in the United States with a high mortality rate and very limited treatment options. The overall focus of Dr. Baines research program is to identify and validate novel molecular targets in pancreatic cancer which can be targeted by potential cancer therapeutics. Additionally, his lab aims to understand the role of these molecular targets in the development and progression of normal cells transforming into cancer cells of the pancreas. Currently, Dr Baines studies the functional significance of the oncogenic Pim kinase family in pancreatic cancer growth and development. He hypothesizes that inhibition of these enzymes will be an effective approach for antagonizing the aberrant growth of pancreatic carcinoma. In addition to working with colleagues in academia, he collaborates with various pharmaceutical companies that are developing Pim inhibitors. Results from his studies will allow for critical validation of these kinases as novel therapeutic targets for pancreatic cancer treatment. Dr. Baines research has been funded by NIH and other grant sources. He has presented his research at various national scientific meetings such as the Society of Toxicology and the American Association for Cancer Research. In addition, Dr. Baines has given invited research seminars at universities such as Duke University, UNC-Chapel Hill, North Carolina Agricultural and Technical (A&T) State University, Indiana University, North Carolina State University, University of Missouri-Kansas City and Massachusetts Institute of Technology (MIT).
                              • Stephen Jackson, PhD
                                Associate Director, Product Applications, Genetic Analysis Division, Life Technologies
                                Biography
                                  Steve Jackson is an Associate Director of Product Applications in the Genetic Analysis division of Life Technologies. Prior to joining Life Technologies, he was Manager and Principle Field Applications Specialist for Nanostring Technologies. At the University of Washington, Department of Genome Sciences, he was an Acting Assistant Professor, exploring basic developmental genetics and neurodegenerative diseases in Drosophila. Dr. Jackson earned his Ph.D in Biochemistry, Biophysics and Genetics at the University of Colorado Health Sciences Center in Denver, CO.
                                • Dan Rhodes, PhD
                                  Head of Medical Science Informatics, Life Technologies
                                  Biography
                                    Dr. Rhodes has a 12-year track record in cancer genomics and bioinformatics, with a significant focus on building systems to enable cutting-edge cancer research. He founded a successful cancer genomics and informatics company, Compendia Bioscience, recently acquired by Life Technologies. To build Compendia, he recruited and trained a talented team of 30 clinical scientists, bioinformaticists, cancer biologists, data curators and software engineers. As a graduate student, he led the development of Oncomine (Rhodes et al, PNAS, 2004; Rhodes et al, Nature Genetics, 2005), a cancer microarray database and data-mining application. Through the use of Oncomine, he contributed to several important discoveries, including the discovery of gene fusions in prostate cancer (Tomlins, Rhodes, et al., Science, 2005), SPINK1 in prostate cancer (Tomlins, Rhodes et al, Cancer Cell, 2008) and AGTR1 in breast cancer (Rhodes et al, PNAS, 2009). Compendia has since extensively expanded the Oncomine platform, and Oncomine is now widely recognized in academia and pharma as the leading cancer genomics data mining resource, with several hundred citations, and 15,000+ users. As Head of Medical Science Informatics at Life Technologies, he has turned his focus to next-generation sequencing data analysis, and leads several collaborations with pharmaceutical companies aimed at discovering novel oncogenic mutations and gene fusions from thousands of exomes and transcriptomes from The Cancer Genome Atlas. In his role as an Adjunct Assistant Professor at the U. of Michigan, he contributes to cancer genome analyses of prostate cancers (Grasso et al, Nature, 2012) and participates in and advises the clinical sequencing initiative MI-ONCOSEQ.
                                  • Adil Daud, MD
                                    Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco School of Medicine
                                    Biography
                                      Dr. Adil Daud, an oncologist, is co-director of the Melanoma Center and a specialist in melanoma and other skin cancers. In addition to caring for patients, he directs melanoma research to better understand the biology of melanoma and to develop new treatments for the disease. Daud has developed and led many clinical trials that have expanded the use of gene therapy for melanoma. Daud earned a medical degree at the Government Medical College in Nagpur, India. He completed an internship and residency in internal medicine at Indiana University Medical Center, followed by a fellowship in hematology-oncology at Memorial Sloan-Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Fla. for seven years. Daud has won numerous awards, including the American Society for Clinical Oncology's Young Investigator award and Castle Connolly's Best Doctors in America award. He is an associate professor of hematology-oncology at UCSF.
                                    • Henry Chang, PhD
                                      Associate Professor, Department of Biological Sciences, Development and Disease, Purdue University
                                      Biography
                                        Dr. Chang received a B.A. in Biochemical Sciences from Harvard College (Cambridge, MA) in 1991. He obtained his Ph.D. (1995) with Dr. Gerald Rubin in the Department of Molecular and Cell Biology at University of California, Berkeley, working on genes functioning downstream of Ras GTPase in the Sevenless receptor tyrosine kinase cascade. His post-doctoral training was with Dr. Ira Mellman in the Department of Cell Biology at Yale University School of Medicine, working on J-domain proteins in Drosophila endocytosis. Dr. Chang has been on the faculty at Purdue University since 2004, and currently holds the rank of associate professor in the Department of Biological Sciences.
                                      • Andrew Armstrong, MD ScM FACP
                                        Associate Professor of Medicine and Surgery, Duke Cancer Institute, Divisions of Medical Oncology and Urology, Duke University
                                        Biography
                                          Andrew J. Armstrong, MD, ScM, is co-program leader of the genitourinary oncology research program, part of the oncology clinical trials shared resource of the Duke Comprehensive Cancer Center. Armstrong is an internationally recognized expert in prostate cancer outcomes studies in men with castration-resistant metastatic disease, including nomograms and risk group models on prognosis. His research is focused on the development of experimental therapeutics in advanced prostate cancer, particularly those targeting the PI3 kinase/mTOR pathways, as well as the development of prognostic and predictive biomarkers of treatment efficacy, particularly with a focus on circulating tumor cell biology and epithelial-mesenchymal transition (epithelial plasticity). Armstrong is the principal investigator on four investigator-initiated clinical trials and approximately 10 industry or cooperative group sponsored clinical trials, as well as several correlative science studies. In addition to co-directing a clinical research program in genitourinary malignancies, Armstrong serves on the Duke IRB and cancer protocol committee, and is an active member of the Duke Comprehensive Cancer Centers editorial advisory and fellowship committees, and serves as the editor of the Duke Prostate Center newsletter [link]. Armstrongs laboratory collaborates with the laboratory of Mariano Garcia-Blanco, MD, PhD, a renowned RNA biologist, to study alternative RNA splicing as it applies to prostate cancer metastasis and EMT. After completing his fellowship in medical oncology at Johns Hopkins in 2006, Armstrong received his masters of science in clinical investigation from the Johns Hopkins Bloomberg School of Public Health in 2008. Armstrong is a recipient of a Prostate Cancer Foundation Young Investigator Award (2008-2011), an American Society of Clinical Oncology Young Investigator Award (2005-2008), an American Association for Cancer Research Clinical and Translational Fellowship (2005-2008), and has received a Department of Defense Prostate Cancer Research Program Physician Research Training Award (2010-2015). He serves on the National Comprehensive Cancer Center's prostate cancer guidelines panel. Armstrong has published extensively on prostate cancer experimental therapies and prognostic models, including peer reviewed articles, reviews, and numerous book chapters and abstracts.
                                        • R Claudio Aguilar, PhD
                                          Associate Professor and Assistant Head, Department of Biological Sciences, Purdue University
                                          Biography
                                            Dr. Aguilar obtained his PhD degree in Immunochemistry from the School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. Dr. Aguilar pursued his post-doctoral training at the National institutes of Health in Bethesda, MD in the lab of the well-known cell biologist Dr. Juan Bonifacino. In 2005, after a period as Associate Research Scientist at The Johns Hopkins University (in Dr. Beverly Wendland lab), Dr. Aguilar joined the Faculty of the Department of Biological Sciences at Purdue University. There, his group studies the mechanisms linking endocytosis and signaling in health and disease. In order to pursue its research goals, the Aguilar lab routinely use biophysical, biochemical and genetic approaches.
                                          • Kathryn E Wellen, PhD
                                            Assistant Professor, Assistant Investigator, Abramson Family Cancer Research Institute, University of Pennsylvania Medicine
                                            Biography
                                              Dr. Kathryn Wellen received a PhD from Harvard University in 2006 and performed postdoctoral work at the University of Pennsylvania from 2006-2011. In 2011 she joined the Department of Cancer Biology at the University of Pennsylvania as an Assistant Professor. She is a 2012 Pew Scholar in the Biomedical Sciences and is a recipient of a 2012 Forbeck Scholar Award. Her laboratory's research focuses on elucidating links between cellular metabolism and signaling, with a current emphasis on metabolic regulation of the epigenome.
                                            • Charles M. Perou, PhD
                                              Distinguished Professor of Genetics, Scientific Director of Genomics and Bioinformatics, University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center
                                              Biography
                                                Dr. Perou is a member of the Lineberger Comprehensive Cancer Center, the Carolina Center for Genome Sciences, and the Scientific Director of the UNC Genomics and Bioinformatics Core Facility. He received his Ph.D. in Cellular and Molecular Biology from the Department of Pathology at the University of Utah (1996) where he cloned and characterized the human Chediak-Higashi Syndrome gene. He next performed his postdoctoral training in the laboratory of David Botstein at Stanford University (1997-2000) where he began his genomic studies of human tumors using DNA microarrays. These genomic analyses resulted in the identification of novel subtypes of human breast tumors that predict patient survival times and response to therapy. Dr. Perou's laboratory at UNC is focused on using genomics, genetics, and animal models to decipher the underlying biology of the molecular subtypes of breast cancer, and then using this biological information to develop therapies that are specifically targeted against each of these distinct subtypes of breast cancer.
                                              • Anna Barker, PhD
                                                Co-Director, Complex Adaptive Systems Initiative, Director, Transformative Healthcare Networks, Professor, School of Life Sciences, Arizona State University (ASU)
                                                Biography
                                                  Co-Director of Complex Adaptive Systems at ASU, Dr. Barker designs and implements transformative networks to enable the convergence of knowledge, innovative teams and novel funding approaches to address major problems in biomedicine. Several initiatives are underway, including: the National Biomarker Development Alliance NBDA; a program to re-think diseases that are particularly difficult to diagnose and treat; and a consortium focused on deep phenotyping in silico medicine. Prior to joining ASU, Dr. Barker served for several years as Deputy Director of the National Cancer Institute (NCI) and Deputy Director for Strategic Scientific Initiatives. At the NCI she developed and led or co-led a number of transdisciplinary programs including the: The Cancer Genome Atlas (TCGA); Nanotechnology Alliance for Cancer; Clinical Proteomics Technologies Initiative for Cancer; and the Physical Sciences- Oncology Centers (PS-OCs). She co-chaired the NCI-FDA Interagency Task Force (IOTF) and was founding co-chair of the Cancer Steering Committee of the FNIH Biomarkers Consortium (FNIH-BC). Achievements from these groups included the exploratory IND (IOTF); and oversight of the design and implementation of the ISPY-2 Trial (FNIH-BC). She served as a research scientist and a senior executive at Battelle Memorial Institute for 18 years; and subsequently co-founded and served as the CEO of a public biotechnology company. Examples of her public service include: the National Coalition of Cancer Research; Partner and Member of the Board of Directors of C-Change; Chairperson, C-Change Cancer Research Team; Founding member, Department of Defense (DOD) Breast Cancer Research Program (BCRP) and Chairperson of the Integration Panel (IP); a number of roles for the American Association for Cancer Research (AACR), including the Board of Directors and chairperson, Science Policy and Legislative Affairs Committee; member of NCIs Board of Scientific Counselors, Division of Cancer Etiology; and Chairperson, NCI Cancer Center Support Review Study Section. Dr. Barker has received a number of awards for her efforts in science and advocacy for cancer research. Her research interests include complex adaptive systems science, biomarkers, experimental therapeutics and free-radical biochemistry in cancer etiology and treatment. Dr. Barker completed her M.A. and Ph.D. at The Ohio State University, where she trained in immunology and microbiology.
                                                • Ross L. Cagan, PhD
                                                  Associate Dean of the Graduate School of Biological Sciences and Professor of Oncological Sciences, Icahn School of Medicine at Mount Sinai
                                                  Biography
                                                    Dr. Cagan is a Professor in the Department of Developmental and Regenerative Biology and Associate Dean of the Graduate School of Biological Sciences of the Icahn School of Medicine at Mount Sinai. He is also Co-Founder of the biotechnology company Medros Inc. and Editor-in-Chief of Disease Models and Mechanisms. He is a world-renowned expert in the genetics of nervous system development and, more recently, Dr. Cagan has been a pioneer in using Drosophila for novel approaches to cancer and diabetes. Research in Dr. Cagans laboratory focuses on using the fruit fly Drosophila to develop complex models of diabetes and of breast, lung, colorectal, and thyroid cancers. Taking advantage of a century of powerful genetic tools, his laboratory has developed complex, multigenic disease models designed to model specific aspects of human disease. In addition to studying the mechanisms that direct cancer and diabetes, he has developed a novel robotics-based approach for screening whole animals for novel therapeutic drugs. This approach has helped identify the first chemotherapeutic for Medullary Thyroid Carcinoma, vandetanib. More recent work has used fly genetics to develop polypharmacological drugs and drug cocktails designed to address multiple pathways in a rational manner. His laboratory has also explored the links between diabetes and cancer, demonstrating how dietary sugar combines with specific oncogenes to render tumor insulin hypersensitive.
                                                  • Fred Kramer, PhD
                                                    Professor, Public Health Research Institute, New Jersey Medical School, Rutgers University
                                                    Biography
                                                      Fred Russell Kramer is Professor of Microbiology and Molecular Genetics at the New Jersey Medical School, and has been a Principal Investigator at the Public Health Research Institute for the past 25 years. He graduated from the University of Michigan in 1964 and received his doctorate from the Rockefeller University in 1969. He was on the faculty of the Department of Genetics and Development at Columbia University College of Physicians and Surgeons for 17 years and has been a Research Professor and Adjunct Professor in the Department of Microbiology at New York University School of Medicine for the past 24 years.
                                                    • Michael J Mann, MD
                                                      Associate Professor of Surgery, Division of Adult Cardiothoracic Surgery, Chief of General Thoracic Surgery, University of California, San Francisco, VA Medical Center
                                                      Biography
                                                        Michael J. Mann, M.D. is a leader in the development of genetic and molecular therapies and diagnostics for thoracic and cardiovascular disease. Dr. Mann joined the UCSF Thoracic Oncology Program in 2003 as a cardiothoracic surgeon. He had received an A.B. in synthetic chemistry from Princeton University and an M.D. from Stanford University, and was awarded a Ruth L. Kirschstein National Research Service Award (NRSA) Research Training Fellowship through the NIH. Dr. Mann completed his General Surgery residency at Brigham and Women's Hospital/Harvard Medical School, where he also served on the Faculty of Cardiovascular Medicine, and completed his Cardiothoracic Surgery fellowship at UCSF. Dr. Mann is widely admired for his teaching skills and is Associate Director of the Thoracic Surgery Training Program at UCSF. He holds memberships in numerous professional organizations, including the Society of Thoracic Surgeons, American College of Surgeons, American Heart Association, and the Massachusetts Medical Society. Highly respected by his peers, Dr. Mann was named to the list of U.S. News "Top Doctors;" his areas of clinical expertise include lung cancer, management of metastatic disease in the chest, sarcoma, mesothelioma, and minimally invasive (video-assisted) thoracoscopic surgery. He has received numerous awards including the Cardiovascular Medicine Award for Excellence in Research and the William Randolph Hearst Endowment for Young Investigators. Dr. Mann also serves as a scientific reviewer for numerous professional journals.   While on the faculty at Harvard Medical School, Dr. Mann founded the Cardiovascular Gene Therapy Group. He also invented several novel drug and delivery technologies and helped pioneer the application of gene regulation and vascular biology principles to the problem of coronary bypass graft failure. This led to one of the first large scale programs to evaluate the surgical integration of an advanced molecular therapy. More recently, Dr. Mann's focus on oncogenic signaling pathways and molecular profiles of lung cancer and sarcoma has led to the development and international validation of a molecular diagnostic assay that has enabled personalization of the management of early stage lung cancer. Dr. Mann's research in genetic and molecular therapies has been widely recognized, and he is a founder of the first international co-operative study group designed to harness immense untapped clinical research resources in mainland China. He is currently an Associate Investigator in the UCSF Cardiovascular Research Institute, has served as a scientific advisor to the American Heart Association, to the NIH Recombinant-DNA Advisory Committee and to numerous device and pharmaceutical companies, and his Cardiothoracic Translational Research Laboratory has enjoyed continuous NIH R01 funding since its founding in 2006.
                                                      • Katherine LB Borden, PhD
                                                        Principal Investigator, Structure and Function of the Cell Nucleus research unit, Full Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Instit
                                                        Biography
                                                          Dr Borden is a full professor at the Institute for Research in Immunology and Cancer at University of Montreal. She obtained her PhD with Fred Richards at Yale University in Molecular Biophysics and Biochemistry and trained in NMR and cell biology in London with Andrew Lane at the National Institute for Medical Research and with Paul Freemont at the Imperial Cancer Research Fund (now Cancer Research UK). She has a long standing interest in combining structural, biophysical and cell biological methods to better understand how dysregulated mRNA metabolism can contribute oncogenesis. Currently, she studies the eukaryotic translation initiation factor eIF4E with particular emphasis on its mRNA export functions. Her biophysical and cell biological studies have identified an inhibitor of eIF4E, ribavirin. Ribavirin has been shown to target eIF4E activity in leukemia patients where this correlates with clinical responses including remissions.
                                                        • William M. Gallagher, PhD.
                                                          Associate Professor of Cancer Biology, University College Dublin School of Biomolecular & Biomedical Science
                                                          Biography
                                                            Prof. Gallagher originally graduated from the Department of Biochemistry, UCD in 1993 with a 1st Class Joint Honours degree in Molecular Genetics and Biochemistry. Subsequently, he obtained a PhD in Molecular Oncology from the Cancer Research UK Beatson Laboratories in Glasgow. In 1997, he moved to Paris to undertake a Marie Curie Individual Fellowship at Rhone-Poulenc Rorer (currently Sanofi-Aventis). Afterwards, he returned to Ireland upon receipt of an Enterprise Ireland Post-Doctoral Fellowship (1999-2000) and, subsequently, a Marie Curie Return Fellowship (20002001). In 2001, he was employed in a permanent capacity as College Lecturer at UCD within the former Department of Pharmacology. In 2005, he was appointed Senior Lecturer within the UCD School of Biomolecular and Biomedical Science and was promoted to Associate Professor of Cancer Biology in 2006. From September 2009-August 2011, Prof. Gallagher was the Vice-Principal of Research and Innovation at the UCD College of Life Sciences. He is also a Conway Fellow at the UCD Conway Institute. In 2007, he co-founded OncoMark Ltd., which is a private company centred on the development and application of biomarker panels and associated technologies, on both tissues and biological fluids (www.oncomark.com). Prof. Gallagher is currently the Chief Scientific Officer (CSO) at OncoMark. A major focus of Prof. Gallaghers research work is the identification and validation of candidate biomarkers of breast cancer and melanoma, with particular emphasis on translation of transcriptomic and proteomic datasets into clinically relevant assays. In addition, his team utilises lentiviral-based approaches to investigate the functional relevance of candidate tumour progression-associated genes at both in vitro and in vivo levels, as well as engages in preclinical evaluation of novel anti-cancer agents. Prof. Gallagher previously co-ordinated an FP6 Marie Curie Transfer of Knowledge Industry-Academia Partnership Programme, Target-Breast (www.targetbreast.com), which involved 3 academic and 2 industrial partners across 3 EU countries (which ran from Feb 2006-2010). He currently co-ordinates two analogous FP7 Marie Curie Industry-Academia Partnership and Pathways Programmes, (1) Target-Melanoma, which is focused on identification and validation of novel molecular determinants of melanoma progression [this programme involves 7 partners (5 academic/2 industrial) across 5 EU countries and runs from 2009-2013] and (2) FAST-PATH, which is focused on applying high-performance computing and automated image analysis to fast-track pathological assessment in prostate cancer [this programme involves 6 partners (4 academic/2 industrial) across 3 EU countries and runs from 2011-2015]. Prof. Gallagher is also co-PI and Deputy Co-ordinator of a major Science Foundation Ireland-funded Strategic Research Cluster, Molecular Therapeutics of Cancer (2009-2014) (www.mtci.ie); this is the most extensive research programme in the translational cancer research arena within the Republic of Ireland and involves comprehensive interactions with a range of major pharmaceutical, biotechnology and imaging companies. He is also co-ordinator of a large-scale FP7 collaborative project, entitled RATHER, which is focused on providing new rationalised therapy options for difficult-to-treat breast cancer subtypes (2011-2015). This multi-million euro project involves 6 academic groups and 2 industrial parties across 5 EU countries. His research group is also involved in several other FP7 research programmes as partners, including AngioTox and AngioPredict. Prof. Gallagher has received a number of awards based on his research work to date, including the BACR/AstraZeneca Young Scientist Frank Rose Award in 2004, the St. Lukes Silver Medal Award in 2008 and the NovaUCD 2011 Innovation Award. Prof. Gallagher has had productive collaborative interactions with a variety of other industrial partners throughout his research, and has filed/been awarded multiple patents.
                                                          • Kristin Landis-Piwowar, PhD, MLS
                                                            Assistant Professor, Biomedical Diagnostic & Therapeutic Sciences, , Oakland University
                                                            Biography
                                                              Kristin Landis-Piwowar is an Assistant Professor of Biomedical Diagnostic and Therapeutic Sciences at Oakland University in Rochester, MI. She earned a bachelors degree from Ferris State University in Medical Technology, a Masters degree in Clinical Laboratory Science from Michigan State University and a PhD in Cancer Biology from Wayne State Universitys School of Medicine in the laboratory of Q. Ping Dou. Landis-Piwowar was awarded a post-doctoral fellowship at the University of Michigan, Department of Pathology, where she conducted research to understand CD30 signaling to NFkB in anaplastic large cell lymphoma. Landis-Piwowar joined the faculty at Oakland University in Rochester, MI where she currently holds rank as an Assistant Professor of Biomedical Diagnostic and Therapeutic Sciences. Landis-Piwowar has published more than 25 peer-reviewed journal articles on cancer therapeutics, prevention, and mechanisms of disease and has authored numerous book chapters. Her research interests are centered on the physiologic effects of gold-peptidomimetics in cancer cells, and deciphering a familial relationship among chronic lymphocytic leukemia and hairy cell leukemia.
                                                            • Elahe A Mostaghel, MD, PhD
                                                              Associate Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center
                                                              Biography
                                                                Dr. Mostaghel is a physician scientist specializing in androgen related mechanisms of prostate cancer progression and therapy resistance. She obtained her MD and PhD from Duke University in 2000, followed by residency training at the University of California, San Francisco, and a medical oncology fellowship at the Fred Hutchinson Cancer Research Center (FHCRC). She is currently Assistant Member in the Clinical Research Division at FHCRC, and Assistant Professor in the School of Medicine, Division of Medical Oncology, at the University of Washington in Seattle, where she specializes in the care of patients with genito-urinary malignancies. Dr. Mostaghels research focuses on translational studies addressing hormonal mechanisms of prostate cancer treatment and progression. Her recent work in prostate cancer metastases and xenograft models has identified pathways of cellular androgen transport, tumoral androgen metabolism, intracrine steroidogenesis, and expression of wild type and variant androgen receptors as potential mechanisms of disease progression, suggesting in situ analysis of these parameters can be exploited to individualize the assignment of patients to novel agents targeting these pathways.
                                                              • Jessica C Mar, PhD
                                                                Assistant Professor, Department of Systems & Computational Biology, Assistant Professor, Department of Epidemiology & Population Health, Albert Einstein College of Medicine
                                                                Biography
                                                                  Jessica Mar is an Assistant Professor at the Albert Einstein College of Medicine in the Department of Systems and Computational Biology in the Bronx, New York. The Mar lab investigates how variability of gene expression informs our understanding of how genes and pathways are dysregulated in disease. Dr. Mar received her PhD in Biostatistics from Harvard University in 2008. Previously she was a postdoctoral research fellow at the Dana-Farber Cancer Institute in Boston and a visiting scientist at the European Bioinformatics Institute in the United Kingdom. She is a recipient of a University of Queensland medal and an American-Australian Fulbright award. She is currently an Associate Editor of Genomics.
                                                                • Roberto Chiarle, MD
                                                                  Associate Professor in Pathology, Harvard Medical School, Department of Pathology, Children's Hospital Boston
                                                                  Biography
                                                                    Roberto Chiarle received an M.D. degree from the University of Turin, Italy. Then, he earned a Board in Surgical Pathology from the University of Torino. He did his postdoc research training with Giorgio Inghirami and Michele Pagano at the New York University, where he worked on the molecular pathogenesis of B and T cell lymphomas. He was appointed as Assistant Professor in Pathology and as Attending Physician in Pathology in the University of Turin, Italy in 1999, then promoted to Associate Professor in 2006. In Italy, he started his own lab and worked on the ALK oncogene in human lymphoma, to discover new molecular mechanisms of ALK mediated cell transformation and new ALK specific therapies. From 2008 to 2010, he was Visiting Professor in Pathology in Fred W. Alt lab at the Immune Disease Institute/Childrens Hospital, Boston, where he worked on chromosomal translocations and contributed to develop a new high-throughput method to clone translocations genome-wide from primary B cells. In 2012, he was appointed as Associate Professor of Pathology at Harvard Medical School and started his own lab at the Childrens Hospital Boston. He won numerous grants and awards in Europe, such as the Italian National Premio Sapio Junior Investigator Award, the Italian National prize Carlo Chianello Foundation Research Award, the prestigious ERC Starting Grant from the European Research Council and the research award from the Association for International Cancer Research, UK.
                                                                  • Judd W Moul, MD, FACS
                                                                    James H Semans MD Professor of Surgery, Division of Urologic Surgery, , Director, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center
                                                                    Biography
                                                                      Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland and an attending Urologic Oncologist at the Walter Reed Army Medical Center (WRAMC) in Washington, DC. In addition, he was Director of the Center for Prostate Disease Research (CPDR); a Congress-mandated research program of the Department of Defense based at USUHS and WRAMC. In 2004, he completed a 26-year U.S. Army career, retiring as a full Colonel in the Medical Corps, and became Chief of the Division of Urologic Surgery at Duke. Serving as Chief from 2004 to 2011, he brought innovation and growth to the program. Most notably, he started the Duke Prostate Center, expanded the urology residency training program through a novel collaboration with the Department of Defense and was able to maintain Duke Urology as a top 10 program in the nation throughout his tenure. Dr Moul completed his Urologic Oncology Fellowship at Duke University and graduated Summa Cum Laude from Pennsylvania State University. He earned his medical degree from Jefferson Medical College, where he was elected to Phi Beta Kappa and Alpha Omega Alpha. Dr Moul currently serves on the editorial boards of Prostate Cancer, Prostate Cancer and Prostatic Diseases, BJU International, American Journal of Mens Health, Brazilian Journal of Urology, World Journal of Urology, and Oncology REALTIME. He has published over 500 medical and scientific manuscripts and book chapters and has lectured at national and international meetings. He has appeared on ABC, NBC, CNN, PBS, and other media as a prostate cancer authority. Honors and awards received have included the American Medical Associations Young Physicians Section Community Service Award for his national involvement in prostate cancer patient support groups, the Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, the prestigious Gold Cystoscope Award by the American Urological Association, the Baron Dominique Jean Larrey Military Surgeon Award for Excellence, the Order of Military Medical Merit from the Surgeon General at the US Army, and the Castle Connolly National Physician of the Year award.
                                                                    • Kenan Onel MD, PhD
                                                                      Associate Professor of Pediatrics, Director, Pediatric Familial Cancer Clinic, University of Chicago
                                                                      Biography
                                                                        Kenan Onel, MD, PhD is an Associate Professor of Pediatrics in the Section of Hematology/Oncology, and Director of the Pediatric Familial Cancer Clinic at The University of Chicago. After receiving his undergraduate degree as well as an MA in modern European history at Yale, Dr Onel completed both an MD and a PhD in molecular biology as part of the Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD program. Dr Onel then trained as a pediatrician at the Childrens Hospital of New York, and as a pediatric oncologist at the Memorial Sloan-Kettering Cancer Center. Dr Onels interest in the genetic basis of cancer developed while caring for children with cancer at Memorial Sloan-Kettering, and so, he completed a post-doctoral fellowship in cancer genetics at the Rockefeller University. As a physician/scientist, the goal of Dr Onels research is to understand the genetic contribution to cancer risk and response to therapy using genomic platforms and systems biology strategies. He has been a faculty member at The University of Chicago since 2004.
                                                                      • Len Neckers
                                                                        Senior Investigator, National Cancer Institute, Center for Cancer Research
                                                                        Biography
                                                                          Dr. Neckers received his Ph.D. from the University of Connecticut, completed postdoctoral training at the NIH, and joined the NCI in 1981. He became Chief of the Tumor Cell Biology Section, Medicine Branch, in 1988. An early proponent of translational research, Dr. Neckers pioneered development of oligonucleotide-based therapeutic strategies. Recently, Dr. Neckers has been investigating the role of chaperone proteins in signal transduction. His identification of benzoquinone ansamycins as specific antagonists of the chaperone HSP90 uncovered the importance of this protein for the growth and survival of cancer cells and led directly to the first phase I clinical trial of an HSP90 antagonist as an anticancer agent. Dr. Neckers continues to examine the pivotal role of Hsp90 in cancer cell survival, and participates in the ongoing translational development of Hsp90 inhibitors as novel anti-cancer agents. Dr. Neckers holds several patents and has been the recipient of several NIH Merit and NIH Inventor's Awards.
                                                                        • Jaime Guidry Auvil, PhD
                                                                          Scientific Projects Manager, TARGET, NCI Office of Cancer Genomics
                                                                          Biography
                                                                            Dr. Guidry Auvil is a scientific program officer overseeing large-scale genomics efforts within the Office of Cancer Genomics at the National Cancer Institute.&nbsp; She completed her doctoral work in the Biomedical Sciences program and received her PhD in tumor biology at Georgetown University.&nbsp; In graduate school, Dr. Guidry Auvil studied the effects of cellular adhesion molecules on breast cancer bone metastases and holds a patent for a viable small molecule inhibitor of cadherin-11, which is currently being tested for various therapeutic applications. She also has a background in clinical and psychosocial research and project management in both the biotechnology and healthcare sectors. Dr. Guidry Auvil now manages the NCI pediatric cancer genomics initiative, Therapeutically Applicable Research to Generate Effective Treatments (TARGET).&nbsp;&nbsp;&nbsp;&nbsp; <br />
                                                                          Sponsored By

                                                                          For information on becoming a sponsor or exhibitor, please click here.


                                                                          Continuing Education (CME/CE/CEU) Credits

                                                                          The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                                                          Help

                                                                          General LabRoots Questions

                                                                          For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                                                          Contact us

                                                                          Virtual Events and Webinars

                                                                          Supported Configurations

                                                                          • Operating System Internet Explorer Firefox Chrome Safari
                                                                            Vista IE8+ FF10+ Chrome15+
                                                                            Windows 7 IE8+ FF10+ Chrome15+
                                                                            Windows 8 IE10 FF10+ Chrome15+
                                                                            Mac OS X   FF10+ Chrome15+ Safari5.1+
                                                                          • Cookie settings: session cookies enabled
                                                                          • Browser configuration must have JavaScript enabled
                                                                          • Adobe Flash player 10.2 or later

                                                                          To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                                                          Internet Connection

                                                                          • A minimum of 100Kbps is recommended for audio-only events
                                                                          • A minimum of 300Kbps is recommended for speaker on-video events

                                                                          Computer Equipment

                                                                          • Screen Resolution: Minimum 1024x768
                                                                          • Video Card: 65,000 colors minimum
                                                                          • Sound card and speakers (or headphones) for hearing webcast in full format
                                                                          • Audio Card: 16-bit minimum
                                                                          • RAM: 512MB of free RAM

                                                                          Firewall Protocol

                                                                          • HTTP on port 80 or HTTPS on port 443
                                                                          • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                                                          • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                                                          Work-At-Home Attendees

                                                                          • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                                                          For A Seamless Experience

                                                                          When using a mobile device, FREE Mobile Apps are available:

                                                                          - For viewing Webinars:

                                                                          - For viewing Virtual Events

                                                                          Attendee Guide

                                                                          • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                                                          Virtual Event and Webinar Support:

                                                                          Continuing Education (CME/CE) Support

                                                                          Loading Comments...